Enovis Corporation

ENOV Healthcare Medical Devices

Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024. In the quarter to June 2026, revenue grew 3.23%, EPS grew 96.9%, free cash flow grew 815.8% and total debt fell 7.82%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

19.59 0.24 +1.24%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
195×
Dividend yield
—
F-score
4/9
Altman Z
−0.34
Beneish M
−4.29
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
0.52 0.57 0.68 0.78
P/FCF ratio
18.73 36.30 76.33 76.19
P/Operating CF
15.89 54.44 17.17 21.01
P/B ratio
0.81 0.88 1.02 0.86
EV/Sales
1.07 1.14 1.24 1.37
EV/EBITDA
7.98 9.44 12.65 15.02
EV/FCF
38.71 72.29 139.62 134.43
Current Ratio
1.98 2.04 2.02 2.22
Net Debt/EBITDA
14.38 16.18 16.55 20.61
Debt/Equity
0.87 0.90 0.87 0.67
Earnings Yield
(93.04%) (87.38%) (77.74%) (77.98%)
Free Cash Flow Yield
5.34% 2.76% 1.31% 1.31%
Free Cash Flow per Share
0.54 (0.50) 0.57 0.51
Book value per Share
25.68 25.81 26.14 35.40
Free Cash Flow
31.14 (28.85) 32.29 29.09
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates